Celsion Corporation (NASDAQ:CLSN) Reports Issuance Of New Patents For ThermoDox®

Celsion Corporation (NASDAQ:CLSN) a clinical stage oncology medication advancement firm reported that the USPTO has allowed U.S Utility patent, which is directly pertinent to the process of treating cancer utilizing the firm’s existing ThermoDox® formulation. This claim constitutes intravenous or direct administration of the formulation trailed by heating and spreads coverage time compared to ThermoDox’s existing parent patents.

The buzz

Celsion also reported the issuance of Korean Patent, which links to composition claims bound for a thermally sensitive liposome that comprises all of the components in the firm’s ThermoDox® liposome and one additional lipid. These 2 new patents solidify the international coverage of ThermoDox®, company’s proprietary dosage form of doxorubicin dependent on a heat-activated liposomal base technology, presently in Phase 3 advancement for the cure of primary liver cancer, also named as hepatocellular carcinoma.

The firm’s Phase 3 OPTIMA trial is anticipated to register up to 550 subjects at up to 75 clinical locations in the North America, China, Europe, Taiwan, Southeast Asia and S. Korea and will assess ThermoDox® together with optimized RFA. It will be standardized to at least 45 minutes across all clinical sites and investigators for treating HCC lesions 3-7 centimeters, compared to standardized RFA alone.

Michael H. Tardugno, the CEO, Chairman and President of Celsion, stated that the release of these patents further solidifies company’s growing position as a pioneer in the advancement of directed chemotherapeutics intended to address some of the most complex-to-treat cancers. Together with its arrangement of matter patents, these fresh issuances expand company’s intellectual property portfolio and offers for life cycle management of ThermoDox® into the next decade.

Moreover, by covering the application of ThermoDox®, Celsion supports its exclusivity in numerous major markets across the world where HCC uses epidemic proportions. HCC has the best rate of progression of all cancers with yearly incidence of more than 800,000 new cases and is expected to be the most widespread form of cancer by 2020.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: